Doc, you should be ashamed of yourself! Implying that Gomez couldn't cut it at Merck is downright loathsome, even for you. Gomez did not leave Merck to join DNAPrint. He left Merck in 1988 and DNAPrint did not even start for another 12 years. Let's take another look at his bio from the web site.
Hector J. Gomez, MD, PhD, Chief Medical Officer
Dr Gomez has over twenty years of experience in the biopharmaceutical industry and has managed the development of 10 marketed , mostly in the cardiovascular area. Dr. Gomez has previously served as President and CEO of Transcend Therapeutics, Inc., CEO of Zengen, Inc., Vice President of Medical Affairs for Vertex Pharmaceuticals and as an Executive Director with Ciba-Geigy Corporation. From 1979 to 1988 Dr. Gomez was a Director and Senior Director at Merck/MSDRL Corporation. He currently serves as the Chairman of the Board of Directors of DNAPRINT™ genomics, Inc., PRB Pharmaceuticals, Inc. and Asia Healthcare Ltd. Dr. Gomez received an M.D. from the National University of Colombia, and a PhD from Marquette University and a Diploma in Clinical Pharmacology from Tulane University.
It looks to me that he left Merck to become a CEO. So why did he leave a position as a CEO to work for DNAPrint? Remember he is something like 68 years old. Rather than retire he wanted to put his considerable experience to work for a company that was taking pharmacogenomics to the next stage. IMO, at his stage in life, it is the challenge that drives him. I think he is probably driven to do things no one else has ever done.
Virgil
News 
Market Data 
Discover 
